Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg

Blood

Volumn 122, Issue 13, 2013, Pages 2185-2194

  Baur, Andreas S ^a,b   Lutz, Manfred B ^c   Schierer, Stephan ^a   Beltrame, Luca ^d   Theiner, Gabi ^a   Zinser, Elisabeth ^a   Ostalecki, Christian ^a   Heidkamp, Gordon ^a   Haendle, Ina ^a   Erdmann, Michael ^a   Wiesinger, Manuel ^a   Leisgang, Waltraud ^a   Gross, Stefanie ^a   Pommer, Ansgar J ^a   Kämpgen, Eckhart ^a   Dudziak, Diana ^a   Steinkasserer, Alexander ^a   Cavalieri, Duccio ^e   Schuler Thurner, Beatrice ^a   Schuler, Gerold ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA CATENIN; CD4 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CLASS II TRANSACTIVATOR DEPENDENT ANTIGEN; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; INTERLEUKIN 2 RECEPTOR ALPHA; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER VACCINE; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DENDRITIC CELL; DOWN REGULATION; DRUG MECHANISM; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; UPREGULATION; CONFOCAL MICROSCOPY; DNA MICROARRAY; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MELANOMA; MIXED LYMPHOCYTE CULTURE; MULTIMODALITY CANCER THERAPY; SKIN TUMOR; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL SURVIVAL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DIPHTHERIA TOXIN; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84887355118     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-456988     Document Type: Article

References (48)

1. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-277.
2. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011;186(3):1325-1331.
3. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011;6(4):e18801.
4. Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J. 2010;16(4):342-347.
5. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer. 2006;106(10):2158-2164.
6. Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther. 2003;3(1):179-186.
7. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000;1(1 Suppl 1):S27-S31.
8. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115(12):3623-3633.
9. Mahnke K, Schönfeld K, Fondel S, et al. Depletion of CD41CD251 human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007;120(12):2723-2733.
10. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005;54(6):369-377.
11. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28(6):582-592.
12. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008;6:12.
13. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112(3):610-618.
14. Gajewski T, Matijevich K, Zha Y. Randomized phase II trial of multipeptide vaccination with or without a single pre-vaccine dose of denileukin diftitox in advanced melanoma. J Clin Oncol. 2012;30(suppl):abstract 2582.
15. Thurner B, Röder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223(1):1-15.
16. Schubert W, Bonnekoh B, Pommer AJ, et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol. 2006;24(10): 1270-1278.
17. de Vries IJ, Castelli C, Huygens C, et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res. 2011;17(4):841-848.
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-e80.
19. Martin A, Gutierrez E, Muglia J, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 2001;45(6):871-881.
20. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19(3):425-436.
21. Melillo JA, Song L, Bhagat G, et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol. 2010;184(5):2638-2645.
22. Herrmann A, Kortylewski M, Kujawski M, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010;70(19):7455-7464.
23. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008; 20(2):228-233.
24. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314-1321.
25. Manicassamy S, Reizis B, Ravindran R, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010;329(5993):849-853.
26. Magalhaes JG, Fritz JH, Le Bourhis L, et al. Nod2- dependent Th2 polarization of antigen-specific immunity. J Immunol. 2008;181(11):7925-7935.
27. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011;241(1):206-227.
28. Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis. Genome Res. 2007;17(10):1537-1545.
29. Tarca AL, Draghici S, Khatri P, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009;25(1):75-82.
30. Mashreghi MF, Klemz R, Knosalla IS, et al. Inhibition of dendritic cell maturation and function is independent of heme oxygenase 1 but requires the activation of STAT3. J Immunol. 2008; 180(12):7919-7930.
31. Waters CA, Snider CE, Itoh K, et al. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci. 1991;636: 403-405.
32. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182(2):389-400.
33. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
34. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol. 2010;11(8):647-655.
35. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111-165.
36. Grainger JR, Hall JA, Bouladoux N, Oldenhove G, Belkaid Y. Microbe-dendritic cell dialog controls regulatory T-cell fate. Immunol Rev. 2010;234(1): 305-316.
37. Depaolo RW, Tang F, Kim I, et al. Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Cell Host Microbe. 2008;4(4):350-361.
38. la Sala A, He J, Laricchia-Robbio L, et al. Cholera toxin inhibits IL-12 production and CD8alpha1 dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J Exp Med. 2009; 206(6):1227-1235.
39. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD81 T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE. 2010;5(6): e11144.
40. Lemichez E, Bomsel M, Devilliers G, et al. Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol Microbiol. 1997;23(3):445-457.
41. Fomina AF, Deerinck TJ, Ellisman MH, Cahalan MD. Regulation of membrane trafficking and subcellular organization of endocytic compartments revealed with FM1-43 in resting and activated human T cells. Exp Cell Res. 2003; 291(1):150-166.
42. Muratori C, Cavallin LE, Krätzel K, et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe. 2009;6(3):218-230.
43. Poteryaev D, Datta S, Ackema K, Zerial M, Spang A. Identification of the switch in early-to-late endosome transition. Cell. 2010;141(3):497-508.
44. Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res 2010;2:53-59.
45. Kuzel TM, Li S, Eklund J, et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma. 2007;48(12):2397-2402.
46. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci. 2001;941:1-11.
47. Chesney J, Rasku MA, Klarer AC, Miller DM, Telang S. Effect of denileukin diftitox on serum GMCSF and clinical responses in stage IV melanoma. J Clin Oncol 2011;29(suppl):abstract 2507.
48. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442-447.